SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 26.37 |
| Enterprise Value ($M) | 15.17 |
| Book Value ($M) | -6.01 |
| Book Value / Share | -0.68 |
| Price / Book | -4.39 |
| NCAV ($M) | -9.67 |
| NCAV / Share | -1.09 |
| Price / NCAV | -2.73 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.85 |
| Current Ratio | 0.85 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18.45 |
| Assets | 22.10 |
| Liabilities | 28.11 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.01 |
| Operating Income | -23.45 |
| Net Income | -4.05 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 5.39 |
| Cash from Investing | -0.57 |
| Cash from Financing | 0.43 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 648 | 4,750 | 13.64 | |
| 164 | 10,238 | 1.60 | |
| 1,822 | 5,976 | 30.49 | |
| 1,838 | 12,836 | 14.32 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CYCC – Cyclacel Pharmaceuticals, Inc. | CYCN – Cyclerion Therapeutics, Inc. |
| CYRX – Cryoport, Inc. | DERM – Journey Medical Corporation |
| DMAC – DiaMedica Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io